Delivering tomorrow’s
genetic medicines,

today™

Accelerating Progress for Partners Developing Genetic Medicines

NanoVation helps partners overcome one of the biggest barriers in genetic medicine: enabling nucleic acid delivery beyond the liver with the potency, safety and tissue reach required for next-generation therapies.

We provide a leading, integrated IP portfolio that supports our partners in the development of next-generation genetic medicines. Our lipid nanoparticle (LNP) technologies overcome the limits of existing delivery systems, including enabling extrahepatic delivery to bone marrow, immune compartments and solid tumours.

Our long-circulating LNP (lcLNP^TM) platform has demonstrated improved potency, safety and stability compared to conventional LNP systems. Built on an extensive and continuously growing library of novel lipids and LNP compositions, the platform is designed from day one to be scalable for downstream development.^TM offers comprehensive solutions spanning novel lipid design, RNA modifications and LNP compositions.

Partners choose NanoVation because we combine:

Fit-for-purpose design — customized LNPs built around your target tissue, payload and route of administration.
A comprehensive delivery toolbox — spanning novel lipid design, RNA modifications and LNP compositions, minimizing the need for multiple vendors.
A flexible co-development model — a collaborative approach that integrates seamlessly with your therapeutic program.
Independent validation from leading scientific and industry experts — reinforcing the strength, safety profile and translational potential of our lcLNP™ technology.

Together, we help accelerate the path from concept to lead candidate with delivery solutions that unlock new therapeutic possibilities. Let’s start a conversation around your program needs.

mRNA modifications

Specialty (ionizable) lipids

Surface modifications

LNP compositions

Discover the NanoVation Advantage

Our multidisciplinary team includes world-leading experts in lipid chemistry, RNA design and nucleic acid delivery

NanoVation Therapeutics^TM expertise spans mRNA synthesis and LNP formulation, through to preclinical trials and delivery optimization.

Our world-leading team has the know-how for end-to-end collaboration in the drug development process, empowering partners to rapidly develop their genetic medicines.

Our team

Cross-section of a lipid nanoparticle showing encapsulated genetic material

Our next-generation platform technologies use lipid nanoparticles to deliver nucleic acids to a variety of tissues

NanoVation Therapeutics^TM develops scalable, nucleic acid-agnostic lipid nanoparticle (LNP) formulations customized for specific targets, payloads and routes of administration.

We’re delivering tomorrow’s genetic medicines, today.

Exterior of the UBC building that houses NanoVation's headquarters

NanoVation Therapeutics™ is headquartered in Vancouver, BC, Canada

International headquarters

2nd Floor, 2665 East Mall
Vancouver, BC
V6T 1Z4, Canada



European Office

Unter den Linden 10
10117 Berlin
Germany



Map of the world with NVTx's HQ in Vancouver indicated, as well as its European Office in Berlin.

Get in touch

Our toolbox

Unique ionizable lipid libraries

NanoVation Therapeutics^TM uses bucket chemistry to create extensive lipid libraries at a low cost, with easier synthesis, at a higher yield, and with a higher therapeutic index.

Diagram illustrating the efficacy of mRNA delivery to the liver using LNPs

High-yield✓

Biodegradable✓

Improved potency✓

Our toolbox

LNP compositions

NanoVation Therapeutics^TM develops scalable, nucleic acid-agnostic lipid nanoparticle (LNP) formulations customized for specific tissues, different nucleic acid payloads and routes of administration.

Rationally designed lipid nanoparticles (LNPs) for a variety of tissues including: delivery to bone marrow, immune compartments, and solid tumors.
Nucleic agnostic: Encapsulating a variety of payloads (siRNA, mRNA, DNA, etc.).
Rigorously characterized for nucleic acid and lipid content, entrapment, particle size and polydispersity.

lcLNP delivery

beyond the liver

lcLNP safety

improved profile

lcLNP potency

enhanced in bone marrow

The long-circulating LNP (lcLNP™)

NanoVation’s flagship technology – the long-circulating LNP (lcLNP™) – enables the functional delivery of nucleic acids to extrahepatic tissues including bone marrow, tumors, and skin.

Extended systemic circulation for efficient extrahepatic delivery.
Improved safety profile.
Enhanced efficacy in extrahepatic tissues.

Our toolbox

Surface modifications

NanoVation Therapeutics^TM expands the range of surface modifications to improve tolerability and increase target specificity. This includes PEGless LNP compositions as well as opportunities to modify our lcLNP technology with targeting ligands.

NTx toolbox

mRNA modifications

NanoVation Therapeutics^TM develops new mRNA modifications and manufacturing strategies that improve expression kinetics and storage stability while increasing translation and cellular specificity.

In-house in vitro mRNA synthesis from DNA templates with optimized translational efficiency and stability
Different mRNA constructs available for a variety of biological applications.
In vitro transcribed mRNA characterized for purity, capping efficiency and endotoxin levels.
Novel proprietary RNA caps that greatly increase the efficiency of mRNA translation.

Delivering tomorrow’s genetic medicines,

Accelerating Progress for Partners Developing Genetic Medicines

Our next-generation platform technologies use lipid nanoparticles to deliver nucleic acids to a variety of tissues

lcLNP delivery

lcLNP safety

lcLNP potency

Delivering tomorrow’s
genetic medicines,